In a report released today, Andrew D’silva from B.Riley FBR maintained a Buy rating on Intricon Corp (IIN), with a price target of $48. The company’s shares opened today at $24.22, close to its 52-week low of $20.95.
D’silva wrote:
“IntriCon (IIN) reported 1Q19 results AMC Monday, 4/29, and posted a top line/EPS/adj. EBITDA of $30.1M/$0.08/$1.8M, versus our/consensus estimates of $30.7M/$0.09/$2.1M and $29.9M/$0.11/$2.2M, respectively. The slight top-line miss was primarily due to hearing health related sales as the medical segment was in line with our projections, growing 31% Y/Y to $20.8M. Growth in the segment was largely tied to increased sales of continuous glucose monitoring (CGM) components for Medtronic’s (MDT) Diabetes Group. The bottom-line miss was primarily tied to gross margins coming in below our estimates. Management maintained its 2019 guidance, which calls for a top line between $128M-$133M and GMs between 30%-31.5%.”
According to TipRanks.com, D’silva is a 4-star analyst with an average return of 7.0% and a 39.6% success rate. D’silva covers the Healthcare sector, focusing on stocks such as EyePoint Pharmaceuticals Inc, Sensus Healthcare Inc, and Anixa Biosciences Inc.
Currently, the analyst consensus on Intricon Corp is a Moderate Buy with an average price target of $46.50.
See today’s analyst top recommended stocks >>
The company has a one-year high of $76.80 and a one-year low of $20.95. Currently, Intricon Corp has an average volume of 169K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Intricon Corp. engages in the design, development, engineering, manufacture, and distribution of miniature and micro-miniature body-worn devices. It operates through the Body-Worn Device and Hearing Health Direct-To-Consumer segments. The Body-Worn Device segment comprises medical, hearing health, and professional audio markets.
